_ap_ufes{"success":true,"siteUrl":"howtotreatpoisonivy.com","urls":{"Home":"http://howtotreatpoisonivy.com","Category":"http://howtotreatpoisonivy.com/category/poison-ivy-news/","Archive":"http://howtotreatpoisonivy.com/2015/04/","Post":"http://howtotreatpoisonivy.com/go-ahead-little-goat-eat-some-poison-ivy-it-wont-hurt-a-bit/","Page":"http://howtotreatpoisonivy.com/5-myths-treating-poison-ivy-rashes/","Nav_menu_item":"http://howtotreatpoisonivy.com/96/"}}_ap_ufee

November 15, 2018

Poison ivy It's getting stronger and tougher

Mark Laliberte is used to getting poison ivy, but the reaction he suffered in July was the worst ever.

The 37-year-old Candia man was clearing brush on his property when he slipped into some bushes.

“I didn’t see it, but once I fell into it, I knew it was poison ivy. I ran inside and showered, but it was too late. It was all over my face and neck, particularly on my left side,” he said.

Beth Almon’s doctor told her she has the worst case of poison ivy she’s ever seen. After battling the itch for three weeks, Almon is now on her second batch of Prednisone, a drug used to treat severe allergic reactions.

“This year, for some odd reason I can’t get rid of it out of my system,” said Almon, 32, of Raymond.

The reason for the severe cases may have something to do with changes in the poison ivy plant caused by higher levels of carbon dioxide in the atmosphere, experts say.

Poison ivy is thriving and becoming much more potent, according to Lewis H. Ziska, a research weed ecologist with the U.S. Department of Agriculture.

Ziska has studied the effects of carbon dioxide on plants and has found that it’s changing the chemistry of the urushiol oil in poison ivy, making it more toxic and more likely to cause a skin reaction.

His research looked at how plants react to more sunlight appearing in forests that have become fragmented, especially in urban areas. Ziska found that poison ivy flourishes, spreading faster and becoming more potent.

“Poison ivy tends to do better than most of the plant species we looked at. It’s able to take in the additional carbon dioxide and convert it into additional growth,” he said.

While she hasn’t seen more poison ivy sufferers than usual, Dr. Ellen Bernard of Epping Regional Health Center said there are treatments available to ease the itching and clear things up. Topical steroids can be used, but more severe cases may require an oral steroid.

Susan Chadwick, director of marketing at Derry Medical Center, said she takes steps to avoid poison ivy, but still ended up with a case in July.

“I’m very sensitive to it, so I try like the devil to avoid it,” said Chadwick, whose colleague also suffered a severe reaction this summer and ended up on Prednisone.

jschreiber@newstote.com

Original link:

Poison ivy It's getting stronger and tougher

Poison ivy It's getting stronger and tougher

Mark Laliberte is used to getting poison ivy, but the reaction he suffered in July was the worst ever.

The 37-year-old Candia man was clearing brush on his property when he slipped into some bushes.

“I didn’t see it, but once I fell into it, I knew it was poison ivy. I ran inside and showered, but it was too late. It was all over my face and neck, particularly on my left side,” he said.

Beth Almon’s doctor told her she has the worst case of poison ivy she’s ever seen. After battling the itch for three weeks, Almon is now on her second batch of Prednisone, a drug used to treat severe allergic reactions.

“This year, for some odd reason I can’t get rid of it out of my system,” said Almon, 32, of Raymond.

The reason for the severe cases may have something to do with changes in the poison ivy plant caused by higher levels of carbon dioxide in the atmosphere, experts say.

Poison ivy is thriving and becoming much more potent, according to Lewis H. Ziska, a research weed ecologist with the U.S. Department of Agriculture.

Ziska has studied the effects of carbon dioxide on plants and has found that it’s changing the chemistry of the urushiol oil in poison ivy, making it more toxic and more likely to cause a skin reaction.

His research looked at how plants react to more sunlight appearing in forests that have become fragmented, especially in urban areas. Ziska found that poison ivy flourishes, spreading faster and becoming more potent.

“Poison ivy tends to do better than most of the plant species we looked at. It’s able to take in the additional carbon dioxide and convert it into additional growth,” he said.

While she hasn’t seen more poison ivy sufferers than usual, Dr. Ellen Bernard of Epping Regional Health Center said there are treatments available to ease the itching and clear things up. Topical steroids can be used, but more severe cases may require an oral steroid.

Susan Chadwick, director of marketing at Derry Medical Center, said she takes steps to avoid poison ivy, but still ended up with a case in July.

“I’m very sensitive to it, so I try like the devil to avoid it,” said Chadwick, whose colleague also suffered a severe reaction this summer and ended up on Prednisone.

jschreiber@newstote.com

View this article:

Poison ivy It's getting stronger and tougher

New Allegra- Anti-Itch Cream Introduced by Sanofi-Chattem for Poison Ivy and Itchy Skin

New Allegra- Anti-Itch Cream Introduced by Sanofi-Chattem for Poison Ivy and Itchy Skin

Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream are now available in drug, grocery and mass merchandiser stores nationwide. Chattem, Inc., the Consumer Healthcare Division of Sanofi US and the makers of Allegra Allergy, introduced the Anti-Itch Creams to its family of products to help provide itch relief from reactions to skin irritations.

Allegra Anti-Itch Cooling Relief provides fast cooling relief for hot, itchy skin while Allegra Anti-Itch Intensive Relief provides moisturizing relief for itchy skin or dry and irritated skin. Both products provide temporary relief from the pain and itching associated with insect bites, minor skin irritations, sunburn, rashes due to poison ivy, poison oak or poison sumac, and minor cuts and scrapes. They also temporarily protect and help relieve chapped or cracked skin.

“We identified an opportunity in the topical anti-itch category and leveraged our experience with Allegra Allergy to introduce a new product for common skin irritations that not only helps stop the itch but also provides a moisturizing benefit,” said John Stroud, Executive Vice President, Marketing, Chattem.

Itchy skin can be triggered by a chemical in a person’s body called histamine. Histamine is a person’s immune system reacting to an irritant, like an insect bite or poison ivy. Allegra Anti-Itch Cream acts as an antihistamine, going beneath the surface of the skin to stop the itch at its source. In addition, the moisturizers and vitamins A, C and E in Allegra Anti-Itch Cream help soothe the skin, and the allantoin protects the skin while it gets back to normal after scratching.

Allegra Anti-Itch Cream is indicated for adults and children ages 2 and up. The suggested retail price is $4.99-$6.99. For additional information on the Allegra family of products, please visit www.allegra.com. Follow us on Facebook and Twitter.

anit-itch poison ivy itchy skin
New Allegra- Anti-Itch Cream Introduced by Sanofi-Chattem for Poison Ivy and Itchy Skin

About Allegra®
Allegra Allergy has been providing allergy sufferers with relief of symptoms from indoor and outdoor allergies for more than 15 years. The Allegra family of products is available without a prescription in drug, grocery, mass merchandiser and club stores nationwide.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (SAN) and in New York (SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.

About Chattem
In March 2010, Chattem, Inc. became a wholly-owned subsidiary of the sanofi-aventis Group, as the consumer healthcare division of Sanofi US. Chattem is more than 130 years old and is a leading manufacturer and marketer of branded consumer healthcare products, toiletries and dietary supplements across niche market segments in the United States. For more information, please visit Chattem’s website at www.chattem.com

Forward Looking Statements

anti-itch poison ivy itchy skin
New Allegra- Anti-Itch Cream Introduced by Sanofi-Chattem for Poison Ivy and Itchy Skin

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

New Allegra- Anti-Itch Cream Introduced by Sanofi-Chattem for Poison Ivy and Itchy Skin

New Allegra- Anti-Itch Cream Introduced by Sanofi-Chattem for Poison Ivy and Itchy Skin

New Allegra- Anti-Itch Cream Introduced by Sanofi-Chattem for Poison Ivy and Itchy Skin

Wordpress SEO Plugin by SEOPressor